These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 36455198)

  • 21. Targeting BCL2 with venetoclax is a promising therapeutic strategy for "double-proteinexpression" lymphoma with
    Uchida A; Isobe Y; Asano J; Uemura Y; Hoshikawa M; Takagi M; Miura I
    Haematologica; 2019 Jul; 104(7):1417-1421. PubMed ID: 30523053
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oridonin Synergistically Enhances the Pro-Apoptotic Effect of Venetoclax on Acute Myeloid Leukemia Cells by Inhibiting AKT Signaling.
    Chen L; Li D; Guo X; Cheng C; Wei X
    Front Biosci (Landmark Ed); 2023 Sep; 28(9):195. PubMed ID: 37796705
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa/Bim/Mcl-1/p-Chk1 axis.
    Zhang J; Wang Y; Yin C; Gong P; Zhang Z; Zhao L; Waxman S; Jing Y
    Cell Death Dis; 2022 Apr; 13(4):379. PubMed ID: 35443722
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells.
    Rahmani M; Nkwocha J; Hawkins E; Pei X; Parker RE; Kmieciak M; Leverson JD; Sampath D; Ferreira-Gonzalez A; Grant S
    Cancer Res; 2018 Jun; 78(11):3075-3086. PubMed ID: 29559471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia.
    Wang E; Pineda JMB; Kim WJ; Chen S; Bourcier J; Stahl M; Hogg SJ; Bewersdorf JP; Han C; Singer ME; Cui D; Erickson CE; Tittley SM; Penson AV; Knorr K; Stanley RF; Rahman J; Krishnamoorthy G; Fagin JA; Creger E; McMillan E; Mak CC; Jarvis M; Bossard C; Beaupre DM; Bradley RK; Abdel-Wahab O
    Cancer Cell; 2023 Jan; 41(1):164-180.e8. PubMed ID: 36563682
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anlotinib synergizes with venetoclax to induce mitotic catastrophe in acute myeloid leukemia.
    Wang D; He J; Liu S; Zhang H; Tang D; Chen P; Yang M
    Cancer Lett; 2024 Jul; 593():216970. PubMed ID: 38763475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological Inhibition of PIP4K2 Potentiates Venetoclax-Induced Apoptosis in Acute Myeloid Leukemia.
    Lima K; Carvalho MFL; Pereira-Martins DA; Nogueira FL; de Miranda LBL; Nascimento MCD; Cavaglieri RC; Schuringa JJ; Machado-Neto JA; Rego EM
    Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069220
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia.
    Luedtke DA; Su Y; Ma J; Li X; Buck SA; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Lin H; Taub JW; Ge Y
    Signal Transduct Target Ther; 2020 Feb; 5(1):17. PubMed ID: 32296028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia.
    Zhang H; Nakauchi Y; Köhnke T; Stafford M; Bottomly D; Thomas R; Wilmot B; McWeeney SK; Majeti R; Tyner JW
    Nat Cancer; 2020 Aug; 1(8):826-839. PubMed ID: 33123685
    [TBL] [Abstract][Full Text] [Related]  

  • 30. AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill
    Post SM; Ma H; Malaney P; Zhang X; Aitken MJL; Mak PY; Ruvolo VR; Yasuhiro T; Kozaki R; Chan LE; Ostermann LB; Konopleva M; Carter BZ; DiNardo C; Andreeff MD; Khoury JD; Ruvolo PP
    Haematologica; 2022 Jun; 107(6):1311-1322. PubMed ID: 34732043
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models.
    Garg R; Allen KJH; Dawicki W; Geoghegan EM; Ludwig DL; Dadachova E
    Cancer Med; 2021 Feb; 10(3):1128-1140. PubMed ID: 33347715
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cotargeting of Bcl-2 and Mcl-1 shows promising antileukemic activity against AML cells including those with acquired cytarabine resistance.
    Liu F; Zhao Q; Su Y; Lv J; Gai Y; Liu S; Lin H; Wang Y; Wang G
    Exp Hematol; 2022 Jan; 105():39-49. PubMed ID: 34767916
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dexamethasone enhances venetoclax-induced apoptosis in acute myeloid leukemia cells.
    Wang H; Zhou J; Ma X; Jiao C; Chen E; Wu Z; Zhang Y; Pan M; Cui J; Luan C; Ge J
    Med Oncol; 2023 Jun; 40(7):193. PubMed ID: 37261571
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-tumor effect of antibody drug conjugate ASP1235 targeting Fms-like tyrosine kinase 3 with venetoclax plus azacitidine in an acute myeloid leukemia xenograft mouse model.
    Tsuzuki H; Kawase T; Nakazawa T; Mori M; Yoshida T
    Oncotarget; 2022 Dec; 13():1359-1368. PubMed ID: 36537913
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Venetoclax enhances NK cell killing sensitivity of AML cells through the NKG2D/NKG2DL activation pathway.
    Wu HY; Li KX; Pan WY; Guo MQ; Qiu DZ; He YJ; Li YH; Huang YX
    Int Immunopharmacol; 2022 Mar; 104():108497. PubMed ID: 34999394
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting S100A9 protein affects mTOR-ER stress signaling and increases venetoclax sensitivity in Acute Myeloid Leukemia.
    Fan R; Satilmis H; Vandewalle N; Verheye E; De Bruyne E; Menu E; De Beule N; De Becker A; Ates G; Massie A; Kerre T; Törngren M; Eriksson H; Vanderkerken K; Breckpot K; Maes K; De Veirman K
    Blood Cancer J; 2023 Dec; 13(1):188. PubMed ID: 38110349
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia.
    Pei S; Pollyea DA; Gustafson A; Stevens BM; Minhajuddin M; Fu R; Riemondy KA; Gillen AE; Sheridan RM; Kim J; Costello JC; Amaya ML; Inguva A; Winters A; Ye H; Krug A; Jones CL; Adane B; Khan N; Ponder J; Schowinsky J; Abbott D; Hammes A; Myers JR; Ashton JM; Nemkov T; D'Alessandro A; Gutman JA; Ramsey HE; Savona MR; Smith CA; Jordan CT
    Cancer Discov; 2020 Apr; 10(4):536-551. PubMed ID: 31974170
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo.
    Liu F; Knight T; Su Y; Edwards H; Wang G; Wang Y; Taub JW; Lin H; Sun L; Ge Y
    Target Oncol; 2019 Jun; 14(3):351-364. PubMed ID: 31115744
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia.
    Cojocari D; Smith BN; Purkal JJ; Arrate MP; Huska JD; Xiao Y; Gorska A; Hogdal LJ; Ramsey HE; Boghaert ER; Phillips DC; Savona MR
    Haematologica; 2022 Apr; 107(4):825-835. PubMed ID: 33853293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EIF4A inhibition targets bioenergetic homeostasis in AML MOLM-14 cells in vitro and in vivo and synergizes with cytarabine and venetoclax.
    Fooks K; Galicia-Vazquez G; Gife V; Schcolnik-Cabrera A; Nouhi Z; Poon WWL; Luo V; Rys RN; Aloyz R; Orthwein A; Johnson NA; Hulea L; Mercier FE
    J Exp Clin Cancer Res; 2022 Dec; 41(1):340. PubMed ID: 36482393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.